GHDX was just upgraded by UA (underground stock alerts- google them ) to a BUY with a new price target of 43 that’s HUGE. i’m subscribed to UA’s free newsletter, their subscriber base is huge, the last time they alerted a buy the stock ended up going up 1350% in a very short period, no way this will happen with GHDX but it’s still very positive. i’ve made over $200k with their free alerts so far so it’s definitely not something to sneeze at.
improvement in product sales came mainly on the back of double-digit growth in test volume across all areas of the company’s business. The increased adoption of the prostate cancer test and the approval of Oncotype DX by National Institute for Health and Care Excellence’s (NICE) also aided the successful results. NICE recognized Oncotype DX as the sole test to predict recommended chemotherapy benefits for patients with early-stage, hormone receptor-positive, invasive breast
During the reported quarter, international product revenues grew 25% year over year to $10.1 million. Genomic provided 21,790 Oncotype DX test results, up 21%
from the year-ago quarter.
Gross profit increased 11.3% year over year to $55.2 million. However, the recent prostate cancer test launch and impact of sequestration led to a contraction of 93
basis points (bps) in gross margin, which stood at 83.7% in the quarter. On the other hand, with a 19.3% rise in operating expenses to $54.7 million, the company
incurred operating profit of a nominal $463 million, down a significant 87.5% from the prior-year quarter. The rise in operating expenses originated from higher
research and development (up 20.0% to $14.7 million), selling and marketing (up 20.8% to $26.0 million), and general and administrative (up 15.7% to $14.0
Genomic Health exited the third quarter with cash and cash equivalents, and short-term marketable securities of $114.0 million, up from $99.1 million at the end of
NICE in the U.K. issued final guidance recommending Oncotype DX as the only multi-gene breast cancer test to guide chemotherapy treatment decisions. Moreover,
Genomic health established node-positive and ductal carcinoma in situ (DCIS) coverage for approximately 1.3 million U.S. lives through a contract with a large Blue Cross Blue Shield state plan.
From Luke Timmerman last week:
Genomic Health. The Redwood City, CA-based company (NASDAQ: GHDX) is widely admired in diagnostics because it proved to skeptical insurers that diagnostics aren’t just cheap commodities anymore—they provide information about health that’s quite valuable. Genomic Health has continued to thrive and grow under two CEOs—Randy Scott and Kim Popovits. It is now rolling out new iterations of its original OncotypeDx product that predict the risk of recurrence for patients with prostate and colon cancer, proving it’s not a one-hit wonder in breast cancer. By showing the way in molecular diagnostics, Genomic Health has inspired other entrepreneurs to think big about how new instruments can be used to better predict and prevent disease before doctors have to turn to high-priced and often-toxic therapies. The company could be highly profitable tomorrow if it wanted to be, but instead it chooses to get by on low margins while continuing to invest in the future. It’s a sure sign of a company with a view toward long-term excellence.
Ok Fellas, I AM IN THE MONEYYYYYYY. I am well in the green on the shorts and will cover and go long soon. I will let you know so you can actually follow and make money this time around. Giggle Giggle
Ray James downgrade is the official word..Those impatient investors hate these yearly doubles.tested 200 day today with a bottoming tail.
NOW THAT IS WHAT I A TALKING ABOUT!!!!!! MO MONEY IN my pocket!! We got some good PUMPERturds here. PUMP PUMP PUMP Giggle Giggle
Actually, that is the Zacks analyst report. You should take comfort from the knowledge that Zacks has never been right about this stock or company.
Genomic Health, Inc. : NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients
09/25/2013 | 05:31am US/EasternRecommend:
REDWOOD CITY, Calif., Sept. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its final guidance recommending Oncotype DX(®) as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone receptor-positive, invasive breast cancer. Consistent with leading international breast cancer treatment guidelines, including ASCO(®), NCCN(®), ESMO(®) and St. Gallen, NICE's recommendation recognizes the unparalleled evidence of the clinical validity of the Oncotype DX test and its ability to enable physicians and their patients to make more informed, individualized decisions.
"It is encouraging to see growing recognition of the value of genomic testing. Its provision has enhanced the care of breast cancer patients around the world and it will now be available as an option in the UK," said David Miles, M.D., medical oncologist at Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. "NICE's recommendation for the use of Oncotype DX in the UK is an important step forward, enabling physicians and patients to make better-informed treatment decisions based on the biology of an individual patient's breast cancer."
To date, more than 1,500 women in the UK have utilized the Oncotype DX test to help guide their treatment decisions. Breast cancer is the most commonly diagnosed cancer in women, with almost 50,000 people diagnosed each year in the UK. Most of these patients are diagnosed with early-stage, invasive breast cancer and a significant number of them could benefit from this test under the NIC
I followed the Baker Bros and loaded up in the mid 20's. However, there have been several ups and downs since I bought. The downdrafts have been severe enough to make me kick myself for not harvesting some gains by taking something off the table. I'm a strong believer that the prostate test will be a game changer. The Cleveland clinic testing and support bodes well. However, the value will have to be confirmed in several peer reviewed medical journals before there will be really widespread acceptance. Till then I think the sales ramp will be steady in the low double digit range. Eventually insurers will become big backers since the test will save millions of unnecessary procedures. This and geographic expansion will fuel many years of growth I might want to consider a pair trade where I might eventually short the makers/operators of proton treatment for prostate cancer. Competition can always change the landscape but for now GHDX looks to be well situated. I've decided to maintain a strong core holding and write covered calls on about 25% of my holdings when the share price reaches lofty periods.
sblum2000, I told you the entire time my positions and when I bought and sold. Loss money on the last trade her due to several PUMPERTURDS who led us all the BUY BUY banner as always. I am short here now and only up on my shorts .08 so that should make you feel better. I have never lied to you but I can not say the same for your other posters. Giggle Giggle
Ok Fellas, my average is 29.98 for 1,200 shares. It is time to turn the PUMP-O-Matic Machine on for little ole Giggles. Giggle Giggle
Sentiment: Strong Buy